--- title: "Erasca | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295574493.md" datetime: "2026-08-11T20:13:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295574493.md) - [en](https://longbridge.com/en/news/295574493.md) - [zh-HK](https://longbridge.com/zh-HK/news/295574493.md) --- # Erasca | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.14, missing the estimate of USD -0.1142. EBIT: As of FY2026 Q2, the actual value is USD -47.62 M. #### Cash and Marketable Securities Erasca, Inc.’s cash, cash equivalents, and marketable securities totaled $384.3 million as of June 30, 2026, an increase from $341.8 million as of December 31, 2025. The company further strengthened its balance sheet by raising approximately $632.5 million in gross proceeds from an upsized public offering in July 2026, following another upsized public offering in January 2026 that generated approximately $258.8 million in gross proceeds . #### Balance Sheet Data (in thousands) - **Working Capital:** $244,871 as of June 30, 2026, compared to $257,728 as of December 31, 2025 . - **Total Assets:** $435,054 as of June 30, 2026, up from $396,154 as of December 31, 2025 . - **Accumulated Deficit:** - $1,119,728 as of June 30, 2026, compared to - $892,209 as of December 31, 2025 . - **Total Stockholders’ Equity:** $361,869 as of June 30, 2026, up from $325,171 as of December 31, 2025 . #### Operating Expenses (in thousands) - **Research and Development (R&D) Expenses:** For the three months ended June 30, 2026, R&D expenses were $35,900, an increase from $21,170 for the same period in 2025. This increase was primarily due to higher expenses for clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs. For the six months ended June 30, 2026, R&D expenses were $63,165, up from $47,139 for the same period in 2025 . - **In-process Research and Development:** For the three months ended June 30, 2026, in-process R&D was $0, compared to $7,500 for the same period in 2025. For the six months ended June 30, 2026, in-process R&D was $150,000, significantly higher than $7,500 for the same period in 2025 . - **General and Administrative (G&A) Expenses:** For the three months ended June 30, 2026, G&A expenses were $11,719, an increase from $9,455 for the same period in 2025, driven by higher personnel and legal costs. For the six months ended June 30, 2026, G&A expenses were $22,365, up from $19,116 for the same period in 2025 . - **Total Operating Expenses:** For the three months ended June 30, 2026, total operating expenses were $47,619, compared to $38,125 for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $235,530, compared to $73,755 for the same period in 2025 . #### Loss from Operations (in thousands) For the three months ended June 30, 2026, loss from operations was - $47,619, compared to - $38,125 for the same period in 2025. For the six months ended June 30, 2026, loss from operations was - $235,530, compared to - $73,755 for the same period in 2025 . #### Other Income (Expense), Net (in thousands) - **Interest Income:** For the three months ended June 30, 2026, interest income was $3,603, compared to $4,330 for the same period in 2025. For the six months ended June 30, 2026, interest income was $8,052, compared to $9,070 for the same period in 2025 . - **Other Expense, Net:** For the three months ended June 30, 2026, other expense, net, was - $63, compared to - $81 for the same period in 2025. For the six months ended June 30, 2026, other expense, net, was - $41, compared to - $157 for the same period in 2025 . - **Total Other Income (Expense), Net:** For the three months ended June 30, 2026, total other income (expense), net, was $3,540, compared to $4,249 for the same period in 2025. For the six months ended June 30, 2026, total other income (expense), net, was $8,011, compared to $8,913 for the same period in 2025 . #### Net Loss (in thousands) For the three months ended June 30, 2026, net loss was - $44,079, compared to - $33,876 for the same period in 2025. For the six months ended June 30, 2026, net loss was - $227,519, compared to - $64,842 for the same period in 2025 . #### Comprehensive Loss (in thousands) For the three months ended June 30, 2026, comprehensive loss was - $44,629, compared to - $34,089 for the same period in 2025. For the six months ended June 30, 2026, comprehensive loss was - $229,396, compared to - $64,832 for the same period in 2025 . #### Unrealized (Loss) Gain on Marketable Securities, Net (in thousands) For the three months ended June 30, 2026, unrealized loss on marketable securities, net, was - $550, compared to - $213 for the same period in 2025. For the six months ended June 30, 2026, unrealized loss on marketable securities, net, was - $1,877, compared to a gain of $10 for the same period in 2025 . #### Operational Metrics Updated preliminary data from the AURORAS-1 Phase 1 trial in the U.S. showed ERAS-0015 monotherapy had a 57% uORR8wk in second-line or later KRAS G12X pancreatic ductal adenocarcinoma (PDAC) . The treatment demonstrated favorable tolerability with mostly low-grade treatment-related adverse events, no dose-limiting toxicities, and no treatment-related discontinuations . The median relative dose intensity was 100% at both 24 mg QD and 32 mg QD recommended doses for expansion . #### Outlook / Guidance Erasca, Inc. expects its current cash, cash equivalents, and marketable securities, including net proceeds from the July 2026 offering, to be sufficient to fund upcoming key milestones . The company plans to accelerate clinical development of ERAS-0015, with potentially registration-enabling trials in pancreatic and lung cancers expected to initiate in 2027 . Preliminary Phase 1 monotherapy data for ERAS-4001 is anticipated in the second half of 2026, with further ERAS-0015 monotherapy and combination data expected in the first half of 2027 . ### Related Stocks - [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md) ## Related News & Research - [Erasca files Form 3 for President, R&D Charles S. Fuchs](https://longbridge.com/en/news/295705135.md) - [Erasca rilis presentasi korporat soal pengembangan terapi kanker berbasis jalur RAS/MAPK](https://longbridge.com/en/news/295578619.md) - [Erasca grants new R&D chief Charles Fuchs options for 1,278,520 shares under inducement plan](https://longbridge.com/en/news/295443047.md) - [CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026](https://longbridge.com/en/news/295410054.md) - [03:39 ETErasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS](https://longbridge.com/en/news/295372755.md)